Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
In this activity, the faculty focus on the current and emerging therapeutic strategies for the holistic management of vitiligo. This engaging format is designed to help clinicians identify best practices in managing vitiligo and improve outcomes for their patients with this disease.
Target Audience
This educational activity is directed toward dermatologists, dermatology nurse practitioners, physician assistants, registered nurses, and other health care professionals who treat patients with vitiligo.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the quality of life impacts of vitiligo on patients across diverse age groups and cultural backgrounds
- Assess the latest clinical evidence surrounding new and emerging agents for vitiligo treatment
- Formulate individualized treatment plans encompassing novel JAK inhibitors for vitiligo management
- Integrate approaches to foster open communication and trust in the patient-clinician relationship for effective long-term vitiligo management
Andrew F. Alexis, MD, MPH
Professor of Clinical Dermatology
Weill Cornell Medicine
New York, NY
Disclosures: Grants (funds to institution): AbbVie, Amgen, Arcutis, Castle, Dermavant, Incyte, Leo; Advisory Board/Consulting: AbbVie, Allergan, Almirall, Alphyn, Amgen, Apogee, Arcutis, Bausch Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Canfield, Castle, Dermavant, Eli Lilly, Galderma, Genentech, HairDays, Incyte, Johnson & Johnson, Leo, L’Oreal, Novartis, Ortho, Pfizer, Sanofi-Regeneron, Swiss American, Symrise, UCB, VisualDx; Speaker: Aerolase, Elsevier, Janssen, L’Oreal, Regeneron, Sanofi-Genzyme, Scientis, Springer, Wiley-Blackwell, Wolters Kluwer Health; Equipment: Aerolase.
Chesahna Kindred, MD, MBA, FAAD
Kindred Hair & Skin Center
Marriottsville, MD
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Aerolase, Abbvie, Arcutis, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi Grant/Research Funding: Lilly Ownership interest in privately traded companies: Xtresse
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here